Effects of VLCKD in Metabolic Syndrome
Recruiting
N/A
Interventional Study
Diabetes Mellitus, Type 2
Non-alcoholic Fatty Liver Disease
Obesity
Metabolic Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 25 – 65
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 40 (estimated)
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
VLCKD has showed to be an impactful diet on several metabolism aspects and has proven to be useful for preventing and treating diabetes mellitus type 2, overweight, chronic inflammation and fatty liver.
For this reason, the aim of this pilot study is to examinate the potential effect of a VLCKD on a group of patients that contemporarily have DM2, obesity and Non alcholic fatty liver disease (NAFL…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age 25-65
* BMI 30-40 mg/m2
* NAFLD
* DM2 drug-treated (metformin, SGLT2 inhibitors, GLP-1 analogues, DPPIV inhibitors, basal insulin) and HbA1c \> 7 and \< 10 %.
Exclusion Criteria:
* Secondary obesity due to genetic or endocrinologic causes.
* renal disease with eGFR \< 45…
Contacts